SCHEMBL21165190

SCHEMBL21165190

CCN(C)CC(=O)c1cc(C)n(-c2ccc(I)cc2)c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.48
ALDH1A1 P00352 4/20 0.48
MITF O75030 3/20 0.48
MAPT P10636 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
HKDC1 Q2TB90 2/20 0.48
LMNA P02545 2/20 0.48
RAB9A P51151 3/20 0.47
HTT P42858 2/20 0.47
RECQL P46063 1/20 0.46
NOTUM Q6P988 4/20 0.46
HPGD P15428 2/20 0.45
MAPK1 P28482 1/20 0.45
USP14 P54578 3/20 0.44
KDM4E B2RXH2 3/20 0.44
USP7 Q93009 2/20 0.44
MGLL Q99685 1/20 0.44
POLB P06746 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19749190 0.90 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL19501341 0.90 NOTUM (0.58) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL6923175 0.87 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL6922806 0.87 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL17949835 0.87 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL17949730 0.85 ALDH1A1 (0.67) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL19749202 0.84 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL19749200 0.80 USP14 (0.49) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL17949747 0.78 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL6922796 0.78 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MITFMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885ALDH1A1 4165/4885MITF 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.